Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Spinal Muscular Atrophy Market, by Type
1.4.2 Europe Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 Europe Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 Europe Spinal Muscular Atrophy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market
Chapter 4. Europe Spinal Muscular Atrophy Treatment Market by Type
4.1 Europe Type 1 Market by Country
4.2 Europe Type 2 Market by Country
4.3 Europe Type 3 Market by Country
4.4 Europe Type 4 Market by Country
Chapter 5. Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 Europe Injection Market by Country
5.2 Europe Oral Market by Country
Chapter 6. Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 Europe Drug Market by Country
6.2 Europe Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 Europe Spinraza Market by Country
6.2.2 Europe Zolgensma (AVXS-101) Market by Country
6.2.3 Europe Evrysdi Market by Country
6.2.4 Europe Others Market by Country
6.3 Europe Gene Therapy Market by Country
Chapter 7. Europe Spinal Muscular Atrophy Treatment Market by Country
7.1 Germany Spinal Muscular Atrophy Treatment Market
7.1.1 Germany Spinal Muscular Atrophy Treatment Market by Type
7.1.2 Germany Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.3 Germany Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 Germany Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 UK Spinal Muscular Atrophy Treatment Market
7.2.1 UK Spinal Muscular Atrophy Treatment Market by Type
7.2.2 UK Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.3 UK Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 UK Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 France Spinal Muscular Atrophy Treatment Market
7.3.1 France Spinal Muscular Atrophy Treatment Market by Type
7.3.2 France Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.3 France Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 France Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 Russia Spinal Muscular Atrophy Treatment Market
7.4.1 Russia Spinal Muscular Atrophy Treatment Market by Type
7.4.2 Russia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.3 Russia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 Russia Spinal Muscular Atrophy Treatment Market by Drug Type
7.5 Spain Spinal Muscular Atrophy Treatment Market
7.5.1 Spain Spinal Muscular Atrophy Treatment Market by Type
7.5.2 Spain Spinal Muscular Atrophy Treatment Market by Route of Administration
7.5.3 Spain Spinal Muscular Atrophy Treatment Market by Treatment Type
7.5.3.1 Spain Spinal Muscular Atrophy Treatment Market by Drug Type
7.6 Italy Spinal Muscular Atrophy Treatment Market
7.6.1 Italy Spinal Muscular Atrophy Treatment Market by Type
7.6.2 Italy Spinal Muscular Atrophy Treatment Market by Route of Administration
7.6.3 Italy Spinal Muscular Atrophy Treatment Market by Treatment Type
7.6.3.1 Italy Spinal Muscular Atrophy Treatment Market by Drug Type
7.7 Rest of Europe Spinal Muscular Atrophy Treatment Market
7.7.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Type
7.7.2 Rest of Europe Spinal Muscular Atrophy Treatment Market by Route of Administration
7.7.3 Rest of Europe Spinal Muscular Atrophy Treatment Market by Treatment Type
7.7.3.1 Rest of Europe Spinal Muscular Atrophy Treatment Market by Drug Type
Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:
Unique Offerings 
